Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 8:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 55 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 1-lead ECG Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Vital Signs Patch: Automated Monitoring of Vital Signs Measurements in the In-Patient Hospital Setting

NCT02518100
View directory record Official record
Conditions
Automated Measurement of Vital Signs
Interventions
Vital Signs Patch (VSP) System 3-Lead (NEHB) Configuration, Vital Signs Patch (VSP) System 1-Lead (PAL) Configuration
Device
Lead sponsor
LifeWatch Services, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Sep 2, 2026, 8:38 PM EDT
Completed No phase listed Observational

Smartphone Twelve Lead Electrocardiogram Utility In ST-Elevation Myocardial Infarction

NCT03037229
View directory record Official record
Conditions
STEMI
Interventions
Smartphone ECG, Standard 12-lead ECG
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Sep 2, 2026, 8:38 PM EDT
Completed Not applicable Interventional Results available

A Fib Clinic of the Future Using KardiaPro Platform for Chronic Care of Patients With AF After Ablation Procedure

NCT03557034
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Kardia Monitoring
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Sep 2, 2026, 8:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Electrocardiogram Clinical Validation Study

NCT03492554
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
1-Lead ECG, 12-Lead ECG
Other · Device
Lead sponsor
Apple Inc.
Industry
Eligibility
22 Years and older
Enrollment
602 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
5
States / cities
Miami, Florida • Orlando, Florida • The Villages, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Sep 2, 2026, 8:38 PM EDT
Not listed No phase listed Observational

FFR vs. icECG in Coronary Bifurcations

NCT01724957
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Intracoronary ECG
Procedure
Lead sponsor
University National Heart Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Sep 2, 2026, 8:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction Compared to Placebo and a Single Oral Dose of Moxifloxacin

NCT04563845
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3640254, Placebo, Moxifloxacin
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Sep 2, 2026, 8:38 PM EDT
Completed Phase 1 Interventional Results available

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

NCT03388632
View directory record Official record
Conditions
Metastatic Solid Tumors, Treatment-Refractory Cancers
Interventions
rhIL-15, Ipilimumab, Nivolumab, Tumor biopsies, EKG, ECHO, CT Scan
Drug · Procedure · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 2, 2026, 8:38 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Topical Application of Cocaine HCl 4% and 10% on Safety and Efficacy in Local (Topical) Anesthesia

NCT01746940
View directory record Official record
Conditions
Diagnostic, Procedures and Surgeries on or Through Accessible Mucous Membranes, of the Nasal Cavities
Interventions
Cocaine HCl 4% Topical Solution, Cocaine HCl 10% Topical Solution, Placebo Topical Solution
Drug
Lead sponsor
Lannett Company, Inc.
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Bridgeport, Connecticut • Plano, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Sep 2, 2026, 8:38 PM EDT
Recruiting Phase 1 Interventional

Beta-blocker Administration for Cardiomyocyte Division

NCT04713657
View directory record Official record
Conditions
Tetralogy of Fallot, Double Outlet Right Ventricle
Interventions
N-thymidine, Urine Collection, Echocardiogram, Cardiac MRI (CMR), Propranolol Hydrochloride, Placebo, Physical Exam, Specimen Collection
Other · Procedure · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
30 Days to 60 Days
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
3
States / cities
New York, New York • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 2, 2026, 8:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers

NCT06422767
View directory record Official record
Conditions
Hepatitis B
Interventions
Bepirovirsen, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 2, 2026, 8:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy Subjects

NCT01297062
View directory record Official record
Conditions
Healthy Subjects
Interventions
Exenatide, Moxifloxacin, Placebo comparator
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Daytona Beach, Florida • Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Sep 2, 2026, 8:38 PM EDT
Withdrawn Phase 2 Interventional

Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma

NCT06398587
View directory record Official record
Conditions
Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
Interventions
Onvansertib, Gemcitabine, Nab-paclitaxel, Electrocardiography, Magnetic Resonance Imaging, Positron Emission Tomography, Biospecimen Collection, Computed Tomography
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Sep 2, 2026, 8:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Clinical Validation of Non-Contact Vital Signs

NCT07362641
View directory record Official record
Conditions
Vital Sign Evaluation
Interventions
SmartSpectra Vital Signs Monitor measurement
Device
Lead sponsor
Presage Technologies, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 2, 2026, 8:38 PM EDT
Terminated Phase 1 Interventional

Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas

NCT03971734
View directory record Official record
Conditions
High Grade Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioblastoma
Interventions
Regadenoson 0.05mg, Regadensoson 0.1mg, Regadensoson 0.2mg, Regadensoson 0.4mg, Regadensoson 0.7mg, Regadensoson 1.0mg, Regadensoson 1.4mg
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Sep 2, 2026, 8:38 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Detecting Pulmonary Hypertension With the Eko CORE 500 Digital Stethoscope

NCT07136623
View directory record Official record
Conditions
Pulmnary Hypertension
Interventions
Eko CORE 500 phonocardiogram (PCG) recording, Eko CORE 500 three-lead electrocardiogram (ECG) recording
Diagnostic Test
Lead sponsor
Eko Devices, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,513 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 2, 2026, 8:38 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors

NCT01738451
View directory record Official record
Conditions
Cancer
Interventions
GSK2118436 75 mg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Scottsdale, Arizona • Memphis, Tennessee • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Sep 2, 2026, 8:38 PM EDT
Completed Not applicable Interventional

A One Visit Follow Up of Adults With Fabry Disease Who Started Long-term Enzyme Replacement Therapy As Children

NCT04002531
View directory record Official record
Conditions
Quality of Life, Renal Insufficiency, Cardiac Event
Interventions
General and Neurological examination, Vital signs, 12 lead electrocardiogram, Echocardiogram, Blood draw, Urine collection, 2-hour Holter Monitor, Brief Pain Inventory questionnaire, Quality of Life questionnaire
Other · Procedure
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 2, 2026, 8:38 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Atrial Fibrillation Risk Estimation With Single-lead Handheld Electrocardiograms

NCT07468123
View directory record Official record
Conditions
Atrial Fibrillation (AF)
Interventions
1L ECG screening, Patch monitor
Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 2, 2026, 8:38 PM EDT
Completed Not applicable Interventional

Respiratory Disorders Non-invasive Monitoring of Work of Breathing in Outpatients

NCT04003415
View directory record Official record
Conditions
Copd, Asthma, Respiratory Effort, Contactless Vital Sign Monitoring
Interventions
Investigational Device: Contactless heart rate and respiratory rate monitor, Heart Rate (EKG) Monitor, Respiratory rate Monitor, Pulse Oximetry
Device · Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Sep 2, 2026, 8:38 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

SmartWatch ECG Evaluation Trial I

NCT05942274
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
We propose to validate these smartwatch ECG functions to support FDA submissions
Diagnostic Test
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Sep 2, 2026, 8:38 PM EDT
Completed Not applicable Interventional

Effectiveness of the Eko Digital Stethoscope in Capturing Infant ECGs

NCT06382207
View directory record Official record
Conditions
Tachyarrhythmia
Interventions
Eko Duo electronic stethoscope, CORE 500 electronic stethoscope
Device
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
Up to 1 Year
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 2, 2026, 8:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess Cardiac Conduction of GSK1349572

NCT00996021
View directory record Official record
Conditions
Healthy Subjects
Interventions
GSK1349572 250 mg, Placebo Suspension, Moxifloxacin 400 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 24, 2010 · Synced Sep 2, 2026, 8:38 PM EDT
Recruiting No phase listed Observational

VIZ ACCESS HCM - Multi-Site Registry

NCT07103057
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Viz HCM
Device
Lead sponsor
Viz.ai, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia • Evanston, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced Sep 2, 2026, 8:38 PM EDT
Completed Phase 4 Interventional

Predictive Risk Stratification Through T Variability in ICD Patients Without Pacing Indications

NCT00560768
View directory record Official record
Conditions
Sudden Cardiac Death
Interventions
Ovatio VR 6250 or DR6550
Device
Lead sponsor
LivaNova
Industry
Eligibility
Not listed
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
7
States / cities
Sheffield, Alabama • Tarzana, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2015 · Synced Sep 2, 2026, 8:38 PM EDT